 A novel method PCT n. WO 2010007502 A2, 2010 has been developed to obtain platelet gel from umbilical cord blood CBPG. The main advantages so far identified in CBPG as compared to platelet gel derived from adult platelets relate to the lack of microbiological contamination in the former and to a different profile of growth factors concentrations, such as a higher content of VEGF and lower content of TGF in CBPG. Recent developments have led to a procedure in which CBPG can be prepared, stored in a cryopreservation bag and applied to the skin ulcer without breaking the sterility chain. In spite of promising results on allogeneic CBPG, a randomized clinical trial of sufficient statistical power to detect significant advantages clinical and economical will be performed in patients affected by diabetic foot ulcers and randomly treated with CBPG versus standard local medications SLM.This study is a multicenter 8 centers controlled randomized clinical trial. Outcomes: 1 primary objective is to evaluate the number of closed skin ulcers within 4 weeks of treatment with CBPG vs standard local medications; 2 secondary objectives are percent skin ulcer closure area, number and type of adverse events and cost of treatment. Sample size calculation: 95 5 dropout test and 95 5 dropout control patients ensure 80 power to detect as statistically significant p0.05 60 healing in test vs 40 healing in control.Each clinical centre has been invited to enrol 15 treated and 15 control patients, according to local availability in 12 months. CB units are routinely collected after mothers informed consent before and after placenta delivery in accredited public cord blood banks belonging to the Italian Cord Blood Network ITCBN coordinated by the Centro Nazionale Sangue CNS. After storage and transportation at monitored room temperature, the units will be processed for the preparation of CBPG within 48 hours of collection. CBPG will be prepared according to standard procedures with a defined final platelet concentration 0.8-1.2 x 109L. The CBPC units will be finally cryopreserved in a -80C freezer in view of the clinical use of the CBPG, which will require thawing at 37C in a waterbath and activation with Calcium gluconate. For SLM, each clinical center will use their validated standard procedures. 